Citation Impact
Citing Papers
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing
2013
Burden of liver diseases in the world
2018 Standout
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Liver Injury and Disease Pathogenesis in Chronic Hepatitis C
2013
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation
2016
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination
2015
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
2015
The Natural Course of Chronic Hepatitis B Virus Infection and Its Management
2013
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Hepatitis C virus NS5A inhibitors and drug resistance mutations
2014
Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
2013
Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay
2015
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment
2012
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Update in the management of chronic hepatitis B
2013
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
2012
Hepatitis C Virus
2013
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
2015
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
2014
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
2015
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes
2014 StandoutNobel
Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism
2013
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
2015
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
New Methods in Tissue Engineering: Improved Models for Viral Infection
2014 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Works of Rie Mineta being referenced
Influence of amino‐acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
2009
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir
2009
Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks
2009
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
2012
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
2012